Intersect ENT
Intersect ENT (the "Intersectent" stub) was a Menlo Park, California medical-device company that developed steroid-releasing dissolvable sinus implants — the PROPEL and PROPEL mini families and the SINUVA implant — to improve outcomes for chronic sinusitis and ear, nose and throat surgery. Backed by Norwest Venture Partners (Series D lead), Kleiner Perkins, U.S. Venture Partners and Medtronic, it went public and was acquired by Medtronic on 2022-05-13 for roughly $1.1B, with the FTC-mandated divestiture of its Fiagon products. It is a physical medical-device business with no developer platform, public API, SDK, or developer portal; intersectent.com now redirects to Medtronic's PROPEL product page. This record is retained for lineage from the Norwest portfolio harvest and is not an API provider.
Intersect ENT is profiled on the APIs.io network. Tagged areas include Company, Medical Devices, MedTech, Healthcare, and Ear Nose and Throat.
Kin Score
Resources
Company 1
The organization behind the API
Other 1
Properties that don't map to a standard resource type